Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült Államok3. fázis

Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)

A legfontosabb adatok

Hol
Anaheim, Atlanta, Auburn, Boston, Brandon, Cerritos, Chandler, Charleston, Chesterfield, Chicago, Chula Vista, Cincinnati, Colorado Springs, Columbia, Cullman, Denver, Fayetteville, Henderson, Hialeah, Houston, Huntersville, Huntington Beach, Kenner, Lansing, Little Rock, Long Beach, Miami, Miami Lakes, Middletown, Novi, San Antonio, Santa Ana, Southfield, Spokane, St Louis, Stockbridge, Sugar Land, Towson, Tucson és Wyomissing (Egyesült Államok)Mind a 40 helyszín megnézése
Fázis
3. fázis

Neked szólhat?

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 65 év között vagy?

Forrás: NCT06568367: ki vehet részt

Helyszínek itt: Egyesült Államok

  • Anaheim, CaliforniaHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • Atlanta, GeorgiaHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • Auburn, AlabamaHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • Boston, MassachusettsHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • Brandon, FloridaHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • Cerritos, CaliforniaHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • Chandler, ArizonaHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • Charleston, South CarolinaHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • Chesterfield, MissouriHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • Chicago, IllinoisHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • Chula Vista, CaliforniaHospital not named in the registryContact: Study DirectorNo longer taking part
  • Cincinnati, OhioHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • Colorado Springs, ColoradoHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • Columbia, South CarolinaHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • Cullman, AlabamaHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • Denver, North CarolinaHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • Fayetteville, North CarolinaHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • Henderson, NevadaHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • Hialeah, FloridaHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • Houston, TexasHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • Huntersville, North CarolinaHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • Huntington Beach, CaliforniaHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • Kenner, LouisianaHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • Lansing, MichiganHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • Little Rock, ArkansasHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • Long Beach, CaliforniaHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • Miami, FloridaHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • Miami Lakes, FloridaHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • Middletown, New JerseyHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • Novi, MichiganHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • San Antonio, TexasHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • Santa Ana, CaliforniaHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • Southfield, MichiganHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • Spokane, WashingtonHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • St Louis, MissouriHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • Stockbridge, GeorgiaHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • Sugar Land, TexasHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • Towson, MarylandHospital not named in the registryContact: Study DirectorRésztvevőt keres
  • Tucson, ArizonaHospital not named in the registryContact: Study DirectorNo longer taking part
  • Wyomissing, PennsylvaniaHospital not named in the registryContact: Study DirectorRésztvevőt keres

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

A vizsgálat adatai

Ki végzi
Axsome Therapeutics, Inc.
Azonosító
NCT06568367
A regiszteradat frissítve
2026. július 24.
Eredeti leírás
SUSTAIN (Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder) is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel- group trial to assess the efficacy and safety of solriamfetol in adults with excessive sleepiness associated with shift work disorder (SWD).A teljes eredeti leírásKevesebb

A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Solriamfetol in Excessive Sleepiness Associated With Shift Work Disorder

SUSTAIN (Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder) is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel- group trial to assess the efficacy and safety of solriamfetol in adults with excessive sleepiness associated with shift work disorder (SWD).

Bevonási feltételek: Meets International Classification of Sleep Disorders, Third Edition (ICSD-3) criteria for Shift Work Disorder (SWD); Provides written informed consent to participate in the study before the conduct of any study procedures; Male or female, aged 18 to 65 inclusive.

Kizáró feltételek: Prior exposure to solriamfetol/Sunosi, through either a clinical study or prescription; Unable to comply with study procedures; Medically inappropriate for study participation in the opinion of the investigator.

ClinicalTrials.gov NCT06568367